NZ208119A - Silver pseudomonate and pharmaceutical compositions - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £08119 20811 a Priority Date(s): » .

Complete Specification' Filed: lQ."^T^ Class: . . |Qfe j ........... ... • i a • O t i « i « " *3* 0 JUM1987 " * Publication Date: 7.7....!.........

P.O. Journal, No: .. «"Pf • ••«•■ #"• • • • •. r' NEW ZEALAND No.: Date: PATENTS ACT, 1953 COMPLETE SPECIFICATION "SILVER PSEUDCMONftJE AMD USE v - 1 MAY 1987^1 JXV*" /J. ■ 5C?We, BEECHAM GROUP p.I.e., a British Company, of Beecham House, Great West Road, Brentford, Middlesex, England, hereby declare the invention for which tcjt we pray that a patent may be granted to me /us, and the method, by which it is to be performed, to be particularly described in and by the following statement: - (followed by la) 01 » - la- 208119 02 03 04 05 SILVER PSEUDCMDNAIE AND USE THEREOF 06 07 08 The present invention relates to silver 0^£} pseudomonate, compositions containing it and its use in treating pseudomonal infections. 11 12 Pseudomonic acid is an antibiotic produced by 13 aerobically culturing Pseudomonas fluorescens. The i© compound, of formula (I) below, and its salts and esters are disclosed and claimed in UK Patent No. 1 395 16 907. 17 " 18 OH CH, HQY^-'^y^Y0(CH2>8C02H 21 22 23 24 Whilst pseudomonic acid and its salts and esters 26 are active against a variety of human and animal 27 pathogens (see for instance UK Patent Nos. 1 577 730 20^ 1 5^7 545), they are not active at useful levels '.9 against Pseudomonas species. ;0 ;1 Pseudomonas organisms tend to infect burns and ,2 wounds. Such infections are often difficult to treat ,^0 as the organisms are not particularly susceptible to 4 antibiotics. - •] CH3 0 2081 t 9 It has now surprisingly been found that silver pseudomonate is active against Pseudomonas organisms, especially Pseudomonas aeruginosa, the causative agent of 'blue pus' infections.

The silver salt of pseudomonic acid has not been specifically disclosed in the above patents or any other publications and is, therefore, novel.

Accordingly the present invention provides, in one aspect, silver pseudomonate.

The invention also provides silver pseudomonate for use in the treatment of the human or animal body.

Apart from its surprising activity against Pseudomonas, silver pseudomonate has a similar spectrum of activity against pathogens to those of pseudomonic acid and sodium pseudomonate.

Accordingly the present invention also provides silver pseudomonate for use in treating the human or animal body, especially for treating infected wounds and burns.

The invention also provides a process for producing silver pseudomonate which process comprises reacting silver ions and pseudomonic acid or pseudomonate ions in aqueous solution and thereafter recovering the silver pseudomonate so formed.

Suitably the process is effected by adding a source of silver ions to an aqueous solution of pseudomonic acid or a pseudomonate salt, especially sodium pseudomonate. 208119 Suitably the solution of pseudomonic acid or pseudomonate ions is the product of aerobically culturing Pseudomonas fluorescens (NCIB 10586). Such a solution may be the culture medium in which the organisms have been grown or it may have been produced by purifying such a medium for instance by extracting pseudomonic acid from such a culture medium using a polar, organic, water-immiscible solvent as described in EP 0 005 614. Alternatively the solution of pseudomonic acid or pseudomonate ions may be produced % by dissolving pseudomonic acid or preferably a salt thereof, in an aqueous solvent. Preferably the solution is produced by dissolving pure sodium pseudomonate in water.

The source of silver ions is preferably a soluble silver salt such as silver nitrate or silver carbonate.

The invention further provides silver pseudomonate in substantially pure form, preferably at least 75% pure, more preferably at least 90% pure, most preferably at least 95% pure.

If precipitated from solution containing solvents other than water, the silver pseudomonate may be produced in a solvated form including a hydrated form. If precipitated from aqueous solution the silver pseudomonate may be in a hydrated form.

Accordingly the invention further provides solvated, including hydrated, silver pseudomonate.

Silver pseudomonate may be administered as the pure compound (hereinafter referred to as the 'drug') or it may be administered as a pharmaceutical composition in association with a suitable carrier. 01 02 03 04 05 06 07 08 P 11 12 13 S3> 16 17 18 19 21 22 23 24 26 27 II 31 32 3^ 3^ 36 37 38 208H* Accordingly the invention also provides a pharmaceutical formulation comprising silver pseudomonate and a pharmaceutically acceptable carrier therefor.

As used herein the term ■pharmaceutically acceptable' includes 'veterinarily acceptable*.

The formulations may be adapted for administration by any route, and would depend on the disease being treated. Normally, the formulations will be presented as topical solutions or suspensions for application to the skin, ears or eyes. Alternatively the formulations may be dry powders for application as an aerosol, or they may be presented as impregnated dressings for wounds and burns.

For topical application to the skin the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations that may be used for the drug are conventional formulations well known in the art, for example, as described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmeticology published by Leonard Hill Books, and the British Pharmacopoeia. Alternatively the drug may be applied as a dry powder from an aerosol using conventional diluents and propellants.

For topical application to the ear, the drug may be made up into a solution or suspension in a suitable liquid carrier, such as water, glycerol, diluted ethanol, propylene glycol, polyethylene glycol or fixed oils.

For topical application to the eye, the drug is formulated as a solution or suspension in a suitable, sterile aqueous or non-aqueous vehicle. Additives, for 2081 instance buffers such as sodium metabisulphite or disodium edetate? preservatives including bactericidal and fungicidal agents, such as phenylmercuric acetate or nitrate or chlorhexidine, and thickening agents such as hypromellose may also be included.

Particularly suitable topical formulations comprise silver pseudomonate and at least 1% by weight of a poly (substituted or unsubstituted alkylene) glycol or a derivative thereof.

As used herein the term 'poly (substituted or unsubstituted alkylene) glycol' refers to polymers having the following repeating unit - (CH2)n0 - wherein n is an integer, preferably 2 or 3 and to such polymers wherein one or more methylene groups of each repeating unit is substituted. Suitable substituents include alkoxy groups such as methoxy as in polymethoxypropylene glycol. Such polymers are known by a variety of names, for instance when n = 2, as polyethylene glycol, polyoxyethylene, polyoxyethylene glycol and macrogol and, when n = 3, as polypropylene glycol, polyoxypropylene and polyoxypropylene glycol. All these are useful in the invention as are derivatives of these polymers.

Suitable derivatives include ethers and esters of the poly (substituted or unsubstituted alkylene) glycols, such as the macrogol ethers and esters, for 2081 1 instance cetomacrogol, glycofurol, the 'Tweens'* and block copolymers including poly (substituted or unsubstituted alkylene) glycols such as PoloxamerS which are block copolymers of polyethylene glycol and polypropylene glycol for instance the 'Pluronics'*, and cross-linked polyethylene glycol.

The poly (substituted or unsubstituted alkylene) glycols and derivatives thereof may be used singly or various grades and types may be used in combination to achieve the desired physical properties of the formulation.

Preferably the formulation comprises polyethylene glycol or a derivative thereof.

Suitably the formulation comprises from 0.01 to 50% by weight of silver pseudomonate, preferably 0.1 to 25%, more preferably 0.5 to 10% and most preferably about 2% by weight of silver pseudomonate calculated as the free acid. Such formulations comprising only silver pseudomonate and a poly (substituted or unsubstituted alkylene) glycol or derivative thereof will, of course, contain up to 99.99% of the poly (substituted or unsubstituted alkylene) glycol or derivative thereof.

The formulation may comprise additional therapeutic agents such as antibacterial, antifungal, antiviral and antiinflammatory agents, for instance chlortetracycline, miconazole, idoxuridine and phenazone, provided that these are compatible with the * 'Tween1 and 'Pluroni c' are trade names for the above types of polymer. 208119 silver pseudomonate. Silver Pseudomonate tends to undergo a rearrangement reaction in the presence of acid and accordingly acidic agents are unlikely to be compatible with silver pseudomonate.

In a particular aspect the invention provides a topical formulation as described above wherein silver pseudomonate is the sole therapeutic agent.

In another aspect the invention provides a topical formulation comprising silver pseudomonate and at least 1% by weight of polyethylene glycol Or a derivative thereof.

Polyethylene glycols (PEG's) and derivatives thereof are commercially available in a variety of chain lengths and with a variety of consistencies, for instance:- Polyethylene Glycols:- Liquids Semisolids Hard Solids PEG 200 PEG 300 PEG 400 PEG 1000 PEG 1540 PEG 4000* PEG 6000 Polyethylene Glycol derivatives:- Derivative Chemical Composition Consistency Glycofurol Tween 60 Tween 80 Tetrahydrofurfuryl alcohol polyethylene glycol ether Polyoxyethylene Sorbitan monostearate Polyoxyethylene Sorbitan monooleate Liquid Semi-solid Liquid * PEG 4000 is the B.P. nomenclature for PEG with mean molecular weight of 3350. This material is also known as PEG 3350 in U.S.P. nomenclature. 2081 These may be used singly or admixed in suitable proportions to achieve the desired consistency of formulation.

The formulations of the present invention may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

Particularly suitable formulations according to the present invention comprise at least 1% by weight of PEG or a mixture of PEG's, from 0 to 25% by weight of a PEG derivative or mixture of PEG derivatives and from 0.5 to 10% by weight of silver pseudomonate calculated as the free acid.

Preferably the silver pseudomonate represents 1 to 5% of the formulation, most preferably about 2% of the formulation calculated as the free acid.

Formulations of the invention may be produced by conventional pharmaceutical techniques. Thus ointments and creams are conveniently prepared by melting and mixing together the solid or semi-solid PEG's or PEG anailogues or derivatives, and stirring in the therapeutic agent and any other ingredients. The product is then slowly cooled and filled into containers such as collapsible metal or plastic tubes. 01 02 03 04 05 06 07 08 cr~ lV l'l 12 13 8> 16 17 18 19 21 22 23 24 26 27 31 32 2081 1 9 Liquid preparations, such as ear and eye drops, are produced by dissolving the therapeutic agent in the liquid PEG's or PEG analogues or derivatives and the other ingredients are then added. The resulting solution or suspension is distributed into glass or plastic bottles or in single dose packs such as soft gelatin capsules which are then heat sealed.

If necessary the formulation may be milled at any suitable stage of the process.

A suitable sterilisation procedure may be included in the above processes if necessary. Alternatively raw materials are obtained in sterile conditions and the formulations are produced aseptically.

The dosage employed for formulations administered topically will, of course, depend on the size of the area being treated. For the ears and eyes each dose will typically be in the range from 10 to 100 mg of the drug.

The present invention further provides a process for producing a pharmaceutical formulation which process comprises bringing into association silver pseudomonate and a pharmaceutically acceptable carrier therefor.

The present invention also provides a method for treating pseudonaonal infections of human or non-human animals comprising administering a non-toxic anti-pseudomonally effective amount of silver pseudomonate to an infected human or non-human animal. &1 In a particular aspect the invention provides a method for treating wounds or burns infected with Pseudomonas organisms comprising administering a non-toxic anti-pseudomonally effective amount of silver pseudomonate to the wound or burn.

Preferably the above methods are effected by applying a topical formulation to the infected areia.

The invention will now be illustrated with reference to the following Examples and Biological data. *© 01 2081 1 02 Example 1 03 04 Silver Pseudomonate A 05 06 07 Sodium pseudomonate A (1.82g, 4 mmol) and silver 08 nitrate (0.68g, 4 mmol) were stirred in distilled water for 30 min resulting in the formulation of a white gelatinous precipitate. The mixture was centrifuged, 11 the aqueous layer removed and the residue washed with 12 distilled water. The suspension was centrifuged and 13 the residual solid was dried over phosphorus pentoxide under high vacuum for 2 days to yield silver pseudomonate A, m.p. 164-166oc, (855 mg, 35%); 16 vraax(KBr) 3400, 1710, 1645, 1515 era"*1; 5h(CD3)2SO) 17 5.68 (1H, s, H2), 2.12 (3H, s, CH3-15), 1.1 (3H, d, 18 CH3-I4)t 0.85 (3H, d, CH3-17) (Found: C, 49.6; H, 6.7; 19 Ag, 17.8.

C26H43°9A9 requires C, 51.4; H, 7.1; Ag, 17.8%). 21 D 0 12 2081 1 Example 2 Liquid Formulation Silver pseudomonate may be dissolved in PEG 400 and the formulation adjusted, by addition of further PEG 400, to contain 2% by weight of silver pseudomonate.

Example 3 Ointment Formulation PEG 400 PEG 4000 Silver pseudomonate % w/w 59 39 2 Example 4 Lotion Formulation % w/w PEG 400 Ethanol Silver pseudomonate 74 24 2 w 01 2 08119 02 Example 5 03 04 Drop Formulation 05 % w/w 06 PEG 400 74 07 Glycofurol 24 08 Silver pseudomonate 2 <© lu Example 6 n 12 % w/w 13 Cetomacrogol emulsifying ointment 65 ^ Polyethylene glycol 2 00 33 Id Silver pseudomonate 16 01 - 14 - 1 02 03 04 05 BIOLOGIGAL DATA 06 07 08 a) The minimum inhibitory concentrations (MlCs) of silver pseudomonate and sodium pseudomonate were determined against 20 strains of Pseudomonas 11 aeruginosa in Blood Agar Base. Typical results 12 are presented in Table 1. Silver pseudomonate was 13 more active than sodium pseudomonate against all strains tested. 16 b) MlC's of silver and sodium pseudomonate against 17 various pathogenic bacteria were determined by 18 standard methods. Typical results are presented 19 in Tab lie 2.

C D 01 208119 02 03 04 05 06 07 08 0j Table 1 The activity of Sodium Pseudomonate and Silver Pseudomonate against 20 strains of Pseudomonas aeruginosa: Typical MIC's 40 41 42 12 Pseudomonas MIC* ug/ml 13 aeruginosa 14 Sodium Salt Silver Salt 16 NCTC 10662 12,800 128 Hi Dalgleish >128 128 PU7 >128 128 19 W985 >128 128 S41 >128 128 21 R6 0 >128 128 22 Pu4 >128 128 23 R59 >128 . 64 24 T3 >128 128 R3 6,400 128 26 R139 >128 128 27 R22 >128 128 28 W995 >128 128 29 59 >128 128 125 >128 128 31 4 >128 128 32 Fr 13 6,400 128 33 D25 >128 128 34 ATCC 27853 >128 128 W996 >128 128 36 — * MIC determined in serial dilution in Blood Agar Base. Inoculum of 0.001 ml of an overnight Tryptone Soya Broth Culture. Incubated at 37°C overnight. o

Claims (1)

01 02 03 04 05 06 07 08 09 10 11 12 9 15 16 17 1-8 19 & 22 23 24 25 26 27 28 29 o © - 16 - 20811* Table 2 Typical MIC's (uq/ml) against Human Bacteria Organi sm Pseudomonate Salt, MIC (ng/ml) Silver Sodium E. coli NCTC 10418 128 125 P. mirabilis 889 128 125 K. aerogenes A 128 250 Ps. aeruginosa NCTC 10662 128 12800 Pasteurella multocida 1633 0.5 0.25 Haemophilus influenzae Wy21 0.12 0.12 Bacillus subtilis 6633 0. 25 0.25 Corynebacterium xerosis 9755 128 >125 Staph, aureus Oxford 0. 5 0.25 Staph, aureus Russell 0. 5 0.25 Staph, aureus W2827 0.5 0.25 Strep, faecalis I 64 50 Strep, pyogenes R80/421-A 0.25 0.25 Strep, agalactiae 2788-B 1.0 0.5 Strep, spp. 64/848-C 1.0 0.5 208119 ■« * 01 WHAT fWP CLAIM !SJ " I1" 0 2 -Claims 03 04 05 1. a compound silver pseudomonate. 06 07 2. A compound as claimed in claim ly being at least 08 75% pure. 3. A compound as claimed in claim 1 or claim 2, being 11 at least 90% pure. 12 13 4. A compound as claimed in any one of claims 1 to 3, - being at least 95% pure. 16 5. A compound as claimed in any one of claims 1 to 4, 17 in the form of a solvate. 18 19 6. A compound as claimed in any one of claims 1 to 5, 20 in the form of a hydrate. 21 22 7. A process for producing silver pseudomonate which 23 process comprises reacting silver ions and 24 pseudomonic acid or pseudomonate ions in aqueous 25 solution and thereafter recovering the silver 26 pseudomonate so formed. 27 #8, A process as claimed in claim 7, effected by adding a source of silver ions to an aqueous 30 solution of pseudomonic acid or a pseudomonate 31 salt. 3 2 «9. A process as claimed in claim 8, wherein the pseudomonate salt is sodium 35 pseudomonate. - H \ \%
1. 01 - X - 02 10. A process as claimed in claim 7 or claim 8, 03 wherein the solution of pseudomonic acid or 04 pseudomonate ions is the product of aerobically 05 culturing Pseudomonas fluorescens (NCIB 10586). 06 07 11. A process as claimed in any one of claims 7 to 10, 08 wherein the source of silver ions is a soluble 09 silver salt. f 12. A process as claimed in any one of claims 7 to 11, 1*2 wherein the source of silver ions is silver 13 nitrate. 14 o 13. A pharmaceutical formulation comprising silver 16 pseudomonate and a pharmaceutically acceptable 17 carrier therefor. 18 ■ 19 14. A pharmaceutical formulation as claimed in claim 20 13, formulated for topical application. 21 22 15. A pharmaceutical formulation as claimed in claim 23 13 or claim 14, comprising silver pseudomonate and 24 at least 1% by weight of a poly (substituted or 25 unsubstituted alkylene) glycol or a derivative 26 thereof. 27 28 16. A pharmaceutical formulation as claimed in any one of claims 13 to 15, comprising polyethylene glycol or a derivative there of. 31 32 17. A.pharmaceutical formulation as claimed in any one 33 of claims 13 to 16, comprising silver pseudomonate f and at least 1% by weight of polyethylene glycol or a derivative thereof. 36 2083 - y- A pharmaceutical formulation as claimed in any one of claims 13 to 17/ wherein silver pseudomonate is treatment of the human or animal body infected With Pseudomonas organisms. A compound as claimed in claim 19, for use in treating infected wounds and burns infected with Pseudomonas organisms. . A process for producing a pharmaceutical formulation which process comprises bringing into association silver pseudomonate and a pharmaceutically acceptable carrier therefor. A method for treating pseudomonal infections of non-human animals comprising administering a non-toxic anti-pseudomonally effective cimount of silver pseudomonate to an infected non-human animal. A method for treating wounds or burns, of non-human animals, infected with Pseudomonas organisms comprising administering a non-toxic anti-pseudomonally effective amount of silver pseudomonate to the wound or burn." the sole therapeutic agent. A compound as claimed in claim 1, for use in the agents for the applicants